Placenta accreta is a substantially life threatening condition and one of the causes of maternal morbidity and mortality in the world. According to study done in United Kingdom, The estimated incidence of placenta accreta/increta/percreta was 1.7 per 10,000 maternities overall and 577 per 10,000 in women with both a previous cesarean delivery and placenta previa. in a tertiary south Italian center, The incidence increased from 0.12% during the 1970s, to 0.31% during the 2000s.While in United States of America, the prevalence of placenta accreta was 3.7 per 1000 deliveries.
Full Title of Study: “Early Prediction of Placenta Accreta by 2 Dimensional Transvaginal Ultrasound and Color Doppler”
- Study Type: Observational
- Study Design
- Time Perspective: Prospective
- Study Primary Completion Date: December 31, 2019
- Device: two-dimensional ultrasound and color Doppler
- the eligible participants will be searched for signs suggestive of placenta accreta; low implantation of the gestational sac (<4cm from the external os), presence of placental lakes, Disruption of placental-myometrial interface and trophoblast overlapping a uterine scar by 2 dimensional transvaginal ultrasound and Intraplacental dilated vessels, turbulent blood flows and greatly increased periplacental vascularity by Doppler ultrasound by level II sonographer and co-investigator under his supervision using ultrasound device.
Arms, Groups and Cohorts
- placenta accreta
- Having at least one sign suggestive of placenta accreta
- normal placenta
- Never having any of the signs suggestive of placenta accreta
Clinical Trial Outcome Measures
- Confirmation of occurrence of placenta accreta during delivery.
- Time Frame: duration of pregnancy
Participating in This Clinical Trial
1. Low implantation of the gestational sac (<4 cm from external os) by transvaginal ultrasound 2. Presence of placental lakes by transvaginal ultrasound 3. Disruption of placental-myometrial interface by transvaginal ultrasound 4. Trophoblast overlapping a uterine scar (Cesarean section, myomectomy) by transvaginal ultrasound 5. Intraplacental dilated vessels by Doppler ultrasound 6. Turbulent blood flows by Doppler ultrasound 7. Greatly increased periplacental vascularity by Doppler ultrasound Exclusion Criteria:
a) Cases far away from our hospital and expected to be lost to be followed. b) Pregnant women who will refuse to Participate -
Gender Eligibility: Female
Minimum Age: N/A
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
- Lead Sponsor
- Assiut University
- Provider of Information About this Clinical Study
- Principal Investigator: Ahmed Mohamed Abbas, clinical professor – Assiut University
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.